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Abstract 
 
Faecal microbiota transplantation (FMT) has been shown to be highly effective in treating recurrent 
Clostridium difficile infection, but to date there have been no data from the United Kingdom. An electronic 
survey was developed at Portsmouth Hospitals’ National Health Service (NHS) Trust and sent out to UK 
hospital specialists utilizing the contact databases of the British Infection Association and the Royal College 
of Gastroenterologists. A total of 162 responses were received, representing nearly one in every seven of 
the United Kingdom’s infection specialists and a response from one in every two UK NHS acute trusts or 
boards. Ninety-six per cent believe that the evidence base supports the use of FMT, and 94% reported 
consulting on at least one patient a year in whom they would recommend FMT. However, only 22% 
reported FMT use in their institution in the last 10 years, and 6% reported performing more than ten FMTs 
in the last 10 years. Concerns with patient acceptance, donor selection, availability of screened faecal 
solution, feasibility of procedure and availability of local expertise were reported as inhibiting the use of 
FMT. More than 90% of respondents would like access to regional guidelines, prescreened faecal solution 
and expert advice to facilitate implementation, and more than two thirds of respondents would support a 
regional FMT referral centre. A large gap exists in the United Kingdom between physicians desire to use 
FMT and the ability and facilities to provide it as a therapy at the bedside. 
 
  
Introduction 
 
Clostridium difficile infection (CDI) is a major cause of mortality and morbidity. C. difficile was recorded as 
the underlying cause of death for 10 258 patients in England and Wales between 2007 and 2011, and a 
contributing factor in a further 12 687 deaths. Between 2009 and 2011, 91% of CDI deaths in England 
and Wales occurred in National Health Service (NHS) hospitals. Most deaths occur in older people, with 
those aged 85 and over having the highest mortality rate (1099 per million population in 2009–2011) 
(http://www.ons.gov.uk/ons/dcp171778_276892.pdf ). Mortality estimates have varied widely, and rates 
have generally reported to have increased with the widespread circulation of the 027/NAP1/BI strain, with 
30 day all-cause mortality of 23% to 29% in an endemic setting [1–3]. Mortality rates in hospitalized CDI 
patients from Holland in a nonendemic setting were recently published, with a 30-day all-cause mortality 
rate of 13% and a 1-year mortality rate of 37% [4]. 
 
A review of the economic burden of CDI in 2012 reported the cost of a single case of CDI to be between 
£4577 ($6943) and £8843 ($13 414) at 2010 values (approximately £5000 to £10 000 in 2014), with an 
average hospital length of stay of between 17 and 37 days [5]. Patients with multiple recurrent episodes of 
CDI may cost the local healthcare economy significantly more than this [6,7]. Faecal microbiota 
transplantation (FMT) has been shown to be highly cost effective compared to standard therapy, with an 
incremental costeffectiveness ratio of over £10 000 ($17 016) relative to oral vancomycin [8]. 
 
Recurrence occurs in approximately 22% of patients after a first episode of CDI [9, 10]. FMT has increasingly 
been reported as an effective treatment for recurrent CDI, with a 2011 systematic review of 317 patients 
across 27 case series and reports showing an overall cure rate of 92% [11]. In 2013, a Dutch group reported 
the first randomized controlled trial of FMT for recurrent CDI, which showed an overall cure rate of 
94% compared to 31% for standard therapy with high-dose vancomycin [12]. 
 
Although FMT appears to be effective, uptake may be hampered by patient and physician concerns over 
the procedure. Attitudes in the United Kingdom are unknown, but concerns over the ‘yuck’ factor [13], as 
well as the disconnect between physician beliefs and patient willingness to accept FMT [14], have been 
explored in the United States. A survey of gastroenterologists and infectious diseases physicians in the 
Houston, Texas, area in the United States published in 2013 showed a desire for a local referral centre for 
FMT [15]. 
 
We developed a survey to explore the uptake of FMT within the United Kingdom and to identify any 
barriers that might prevent the use of FMT. We also asked about the desire for support through availability 
of prescreened donor faecal solution, expert advice and regional referral centres.  
 The NHS provides free healthcare to all UK citizens and legal immigrants, and supports a network of 
primary, secondary and tertiary care providers. Portsmouth Hospitals’ NHS Trust is a secondary and tertiary 
care provider for over 650 000 individuals on the south coast of England.  
 
Methods 
 
Survey development 
The survey was developed at Portsmouth Hospitals’ NHS Trust following a literature review of research and 
opinion articles concerning FMT. It was designed to be completed in approximately 5 minutes and to 
explore the current uptake and need for FMT and the attitudes of physicians to FMT. It asked about 
current use of FMT and other common therapeutic measures by UK physicians, asked physicians to 
determine how many FMTs they might foresee using and asked about their beliefs regarding FMT. After 
literature review, and from peer discussion, 11 factors were identified that might influence FMT uptake, 
and questions regarding these factors were incorporated. The survey was administered using the web-
based KwikSurveys (http://www.kwiksurveys.com ) site. The survey data was downloaded to a CSV file and 
analysed using descriptive statistics using Microsoft Excel. 
 
Survey participants 
The survey was targeted at consultants and senior trainees in infection and gastroenterology. A short 
request for help completing the survey with an attached hyperlink was forwarded via e-mail with the help 
of the British Infection Association and the Royal College of Gastroenterologists. Mailings occurred in 
December 2013 and June 2014, with survey responses accepted up until collation of results in July 2014. 
 
Results 
 
Characteristics and caseload of respondents 
A total of 161 complete or nearly complete (>75%) responses were returned from 86 unique acute hospital 
trusts or NHS boards. One incomplete response was excluded. A total of 142 responses were received from 
infection specialists, and a further 19 responses were received from gastroenterologists via the Royal 
College of Gastroenterologists. One hundred sixty responses were from the United Kingdom, and 159 were 
from physicians primarily working within the NHS. Table 1 shows the grade and specialty of respondent and 
the average number of CDI consults performed per month. 
 
  
Table 1. Specialty and grade of respondent 
   Average no. of CDI cases consulted per month 
Specialty  Grade  n (%) 0  1–2  3–5  6–10  >10 
Infection  Consultant  104 (65)  1 (1)  41 (39)  43 (41)  15 (14)  4 (4) 
 Senior trainee  24 (15)  0 (0)  8 (33)  10 (42)  2 (8)  4 (17) 
Gastroenterology  Consultant  25 (16)  2 (8)  13 (52)  9 (36)  1 (4)  0 (0) 
 Senior trainee  4 (2)  0 (0)  4 (100)  0 (0)  0 (0)  0 (0) 
Other   4 (2)  1 (25)  2 (50)  0 (0)  0 (0)  1 (25) 
 
CDI, Clostridium difficile infection 
 
Current treatment for CDI 
Respondents were asked which therapies for CDI they had personally recommended (Table 2), with 160 
(99.4%) reporting oral vancomycin, 112 (69.6%) fidaxomicin, 43 (26.7%) colectomy and 33 (20.5%) FMT. 
 
Table 2. Therapy used for CDI 
 
Therapy  n (%) 
Vancomycin (oral)  160 (99.4) 
Metronidazole (oral)  155 (96.3) 
Metronidazole (intravenous)  145 (90.1) 
Fidaxomicin (oral)  112 (69.6) 
Intravenous immunoglobulin  82 (50.9) 
Vancomycin (per rectum)  54 (33.5) 
Colectomy  43 (26.7) 
Faecal microbiota transplant  33 (20.5) 
Rifaximin (oral)  27 (16.8) 
Cholestyramine  6 (3.7) 
Fusidic acid/sodium fusidate (oral)  3 (1.9) 
Teicoplanin (oral)  2 (1.2) 
Nitazoxanide (oral)  1 (0.6) 
Bacitracin (oral)  0 (0.0) 
 
Clostridium difficile infection 
 
 
When asked about current FMT use, 34/161 (21.1%) had used it in the last year, and 36/161 (22.4%) had 
used it in the last 10 years. Of those who had used FMT in the last year, 28/161 (17.4%) had performed one 
to four FMTs, three (1.9%) had performed five to nine FMTs and a further three (1.9%) more than ten 
FMTs. Only nine respondents (5.6%) from four unique trusts or boards (4.4%) reported performing more 
than ten FMTs in the last 10 years. 
 
Perceived need for FMT 
In contrast to the low current usage of FMT, 130 (94.1%) of respondents indicated that they saw at least 
one patient a year who would be suitable for FMT in their institution, and 50 (37.0%) saw more than five 
per year. Only eight (5.8%) reported seeing no suitable patients in a year; these eight were all consultant 
infection specialists. 
When asked about the place of FMT in treatment, 132/141 (93.6%) would recommend FMT in patients who 
had recurrent CDI and whose CDI had failed to respond to high-dose pulse/tapered vancomycin, 72 (51.1%) 
in patients with CDI that had failed to respond to 10 days of high-dose vancomycin, 50 (35.5%) in patients 
with fulminant CDI, 18 (12.8%) in patients with a first recurrence and five (3.5%) as primary therapy. Five 
(3.5%) would never consider recommending FMT. 
 
Facilitators and barriers for FMT use  
Respondents were asked to report how 11 different factors influenced their view of FMT (Table 3). A total 
of 133/138 (96.4%) believed that the evidence base supported the use of FMT, but a majority reported that 
patient acceptance, donor selection, lack of availability of screened faecal solution, feasibility and local 
expertise inhibited the uptake of FMT. 
 
Table 3. Factors influencing use of faecal microbiota transplantation 
 
 Favours use,  Inhibits use,  Neither,  Don’t know, 
Factor n (%) n (%) n (%) n (%) 
Evidence base  133 (96.4)  0 (0.0)  2 (1.4)  3 (2.2) 
Benefit vs. risk  128 (90.8)  1 (0.7)  8 (5.7)  4 (2.8) 
Overall cost  59 (41.8)  14 (9.9)  42 (29.8)  26 (18.4) 
Antimicrobial resistance 86 (61.0)  5 (3.5)  41 (29.1)  9 (6.4) 
Patient safety  78 (55.3)  17 (12.1)  37 (26.2)  9 (6.4) 
Patient acceptance  33 (23.4)  58 (41.1)  37 (26.2)  13 (9.2) 
Donor selection  13 (9.3)  67 (47.9)  45 (32.1)  15 (10.7) 
Cost to local laboratory  14 (10.0)  46 (32.9)  64 (45.7)  16 (11.4) 
Availability of prepared stool  47 (33.6)  66 (47.1)  16 (11.4)  11 (7.9) 
Feasibility and practicality  35 (24.8)  81 (57.4)  19 (13.5)  6 (4.3) 
 of procedure 
Local expertise  45 (32.1)  64 (45.7)  24 (17.1)  7 (5.0) 
 
 
When respondents were asked about factors that might facilitate the uptake of FMT, 135/140 (96.4%) 
would like access to a regional protocol and patient information sheet for FMT, 136 (97.1%) would use 
prescreened faecal solution if it were available regionally, 131 (93.6%) would like access either on or off site 
to a physician experienced in FMT during initial implementation of an FMT programme and 97 (69.3%) 
would like the ability to refer patients to a regional faecal transplant centre. 
 
Discussion 
 
C. difficile costs society dearly in lives, bed-days, and financial expenditure. FMT is an option that may 
reduce mortality, shorten hospital stays and save the healthcare economy money. This survey provides the 
first data on UK physician attitudes to FMT and provides insights into the uptake, beliefs and desires of 
those treating these patients at the bedside. There is clearly a strong risk of selection bias in this form of 
survey, but it includes views from 104 of the 746 consultant infection specialists in the United Kingdom 
(Royal College of Physicians, https://www.rcplondon.ac.uk/sites/default/files/2011_census_-
_registrar_census_-_intro_and_r1-r20.pdf , and Royal College of Pathologists, 
http://www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/C/careersleafletundergrad
uates.pdf ), and the whole survey represents a response from nearly one in two (86/183) of all NHS acute 
trusts or boards. This survey suggests that uptake of FMT in the United Kingdom is currently low, with FMT 
being recommended less frequently than colectomy, but that there is a recognition that more patients 
would benefit from this therapy, with almost every respondent reporting one or more suitable patients a 
year at their place of work. 
 
Physicians overwhelmingly believe that the evidence base favours FMT and that the benefit of this form of 
therapy outweighs the risk. There appears to be understanding about the high cost of treatment for 
recurrent CDI—not only a financial cost, but also a cost in terms of antimicrobial resistance in normal gut 
flora. However, there remains a belief that patients may not want FMT, despite evidence to the contrary 
[13]. Physicians are also rightly concerned about appropriate donor selection, availability of prescreened 
stool and the practicality and feasibility of performing FMT. There is also a recognition that expertise in the 
United Kingdom is currently lacking. When asked if access to regional protocols, patient information 
leaflets, prescreened stool and expert advice would be welcomed, there was an overwhelmingly positive 
response, and two thirds of respondents would be happy to refer patients to a regional centre for FMT. 
 
The development of artificial faecal solution [16] and neater delivery methods are already in development, 
but in the interim, carefully screened donor faeces appears safe in the short term [11]. The use of frozen 
faecal solution [17] will improve accessibility to prescreened stool and appears to have a similar efficacy 
[18]. Delivering frozen FMT via oral capsule has recently been reported to have resulted in good outcomes 
in a small group of patients. This approach is less invasive, is less time-consuming and is likely to improve 
patient acceptability [19]. 
 
FMT was recently incorporated into the European Society of Clinical Microbiology and Infectious Diseases’ 
treatment guidelines for recurrent CDI [20]. However, there is an increasing need for clear national and 
international guidelines standardizing the approach to donor screening, as well as the subsequent 
preparation, storage and delivery of FMT [21, 22]. The governance structures around FMT are yet to be 
clearly defined in many countries. In the United States, the US Food and Drug Administration classed FMT 
as a drug in May 2013, requiring an investigational new drug (IND) application to be submitted before 
performing FMT. However, shortly afterwards, the FDA effectively dropped this requirement 
(http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vacci
nes/ucm361379.htm ) after concerns that the IND application was so onerous that it would greatly restrict 
uptake of FMT. The FDA guidance is currently in draft, and further clarification is expected to follow. In the 
United Kingdom, FMT is regulated under the Human Tissue Act of 2004 and is overseen by the Human 
Tissue Authority, which does not currently provide FMT-specific guidance. The European Medicines 
Agency does not recognize FMT as a rug, and as such has no specific guidance (personal correspondence). 
 
With regard to funding, the United Kingdom remains behind the United States, where remuneration for 
FMT through coding now recognizes not only the cost of performing the procedure but also the cost to the 
laboratory of donor selection and stool screening (http://www.gastro.org/practice/coding/aga-provides-
fmt-coding-guidance ), whilst the UK National Institute for Clinical Excellence coding guidance covers the 
cost of the procedure only. Centres performing FMT must be able to recoup their costs or the NHS may end 
up spending more by buying from private providers. 
 
The United Kingdom should benefit from having a single, unified healthcare provider, and for FMT, this 
benefit should be exploited. Service development between the NHS and the royal colleges could lead to 
national protocols, consent forms and information. Regional centres could provide FMT or could act as 
donor banks for faecal solution, sending out frozen stool aliquots as required. Awareness amongst primary 
care and secondary care physicians could be raised and patient education supported. As interest in FMT for 
other common conditions increases [23], this would potentially put healthcare services on the front foot. 
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